Article information
Full text is only aviable in PDF
REFERENCES
[1]
JI Granda Orive, F Roig Vázquez, JL Rodríguez Hermosa, S Solano Reina, CA Jiménez Ruiz, JL Álvarez-Sala Walther.
Tratamiento del tabaquismo en la enfermedad pulmonar obstructiva crónica.
Prev Tab, 6 (2004), pp. 213-223
[2]
J Camí, E Suñen, JM Carbó, L Coma.
Producción científica española en biomedicina y ciencias de la salud (1994-2000). Informe del Instituto de Salud Carlos III-Fondo de Investigación Sanitaria.
[3]
J Cami, E Suñen Piñol, R Méndez Vásquez.
Mapa bibliométrico de España 1994-2002: biomedicina y ciencias de la salud.
Med Clin (Barc), 124 (2005), pp. 93-101
[4]
JI Granda Orive.
Algunas reflexiones y consideraciones sobre el factor de impacto.
Arch Bronconeumol, 39 (2003), pp. 409-417
[5]
I Rippon, G Lewison, MR Partridge.
Research outputs in respiratory medicine.
Thorax, 60 (2005), pp. 63-67
[6]
R Aleixandre, JC Valderrama, M Castellano, R Simó, C Navarro.
Factor de impacto nacional de las revistas médicas españolas.
Arch Bronconeumol, 40 (2004), pp. 563-569
[7]
IBERPOC Comité Científico del estudio.
Proyecto IBERPOC: un estudio epidemiológico de la EPOC en España.
Arch Bronconeumol, 33 (1997), pp. 293-299
[8]
INE.
Anuario estadístico de España 2004. Morbilidad.
[9]
Mortalidad por enfermedades del aparato respiratorio y enfermedades crónicas del aparato respiratorio en España. Accessed on July 18, 2005.
[10]
JI Granda Orive, F García Río, F Roig Vázquez, JA Escobar Sacristán, T Gutiérrez Jiménez, L Callol Sánchez.
Las palabras clave como herramientas imprescindibles en las büsquedas bibliográficas. Análisis de las áreas del sistema respiratorio a través de Archivos De Bronconeumología.
Arch Bronconeumol, 41 (2005), pp. 78-83
[12]
P Cabrera Navarro, R Pérez Padilla.
EPOC: un nombre ambiguo y 36. un inconveniente en la lucha antitabaco.
Arch Bronconeumol, 40 (2004), pp. 477-479
[14]
J Escarrabil.
Costes sanitarios de la enfermedad pulmonar obstructiva crónica (EPOC).
Arch Bronconeumol, 39 (2003), pp. 435-436
[15]
J de Miguel Díez.
Farmacoeconomía en el asma y en la EPOC.
Arch Bronconeumol, 41 (2005), pp. 239-241
[16]
M Miravitlles, C Murio, T Guerrero, R Gisbert.
On behalf of the DAFNE Study group. Costs of chronic bronchitis and COPD.
Chest, 123 (2003), pp. 784-791
[17]
JF Masa, V Sobradillo, C Villasante, CA Jiménez Ruiz, L Fernández Fau, JL Viejo, et al.
Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional.
Arch Bronconeumol, 40 (2004), pp. 72-79
[18]
A Verdaguer Munujos, S Peiro, J Librero.
Variabilidad en la utilización de recursos hospitalarios en pacientes con enfermedad pulmonar obstructiva crónica (EPOC).
Arch Bronconeumol, 39 (2003), pp. 442-448
[19]
J de Miguel Díez, JL Izquierdo Alonso, París Molina, JM Rodríguez González-Moro, P de Lucas Ramos, G Gaspar Alonso-Vega.
Fiabilidad del diagnóstico de la EPOC en atención primaria y neumología en España. Factores predictivos.
Arch Bronconeumol, 39 (2003), pp. 203-208
[20]
J de Miguel Díez, JL Izquierdo Alonso, JM Rodríguez González Moro, P de Lucas Ramos, J Molina París.
Tratamiento farmacológico de la EPOC en dos niveles asistenciales. Grado de adecuación a las normativas recomendadas.
Arch Bronconeumol, 39 (2003), pp. 195-202
[21]
Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Workshop 2003.
[22]
JA Barberá, G Peces-Barba, AGN Agustí, JL Izquierdo, E Monsó, T Montemayor, et al.
Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica (Normativa SEPAR).
Arch Bronconeumol, 37 (2001), pp. 297-316
[23]
The National Collaborating Centre for Chronic Conditions.
Chronic Obstructive Pulmonary Disease. National clinical guidelines of management of chronic obstructive pulmonary disease in adults in primary and secondary care. NICE Guideline no. 12.
Thorax, 59 (2004), pp. 1-232
[24]
The ATS/ERS COPD Guidelines.
Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease.
[25]
MC Fiore, WC Bailey, SJ Cohen, ST Dorfmann, MG Goldstein, ER Gritz, et al.
Treating tobacco use and dependence.
JAMA, 283 (2000), pp. 3244-3254
[26]
MC Fiore, DK Hatsukami, TB Baker.
Effective tobacco dependence treatment.
JAMA, 288 (2002), pp. 1768-1771
[27]
JE Anderson, DE Jorenby, WJ Scott, MC Fiore.
Treating tobacco use and dependence. An evidence-based clinical practice guideline for tobacco cessation.
Chest, 121 (2002), pp. 932-941
[28]
NF Woolacott, L Jones, CA Forbes, LC Mather, AJ Sowden, FJ Song, et al.
The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: systematic review and economic evaluation.
Health Technology Assessment, 6 (2002), pp. 1-245
[29]
CA Jiménez Ruiz, JI Granda Orive, S Solano Reina, F Carrión Valero, P Romero Palacios, M Barrueco Ferrero.
Recomendaciones para el tratamiento del tabaquismo.
Arch Bronconeumol, 39 (2003), pp. 514-523
[30]
CA Jiménez Ruiz, M Barrueco Ferrero, S Solano Reina, M Torrecilla García, F Domínguez Grandal, JL Díaz-Maroto Muñoz, et al.
Guía de diagnóstico y aproximación terapéutica de la adicción tabáquica. Documento de consenso.
Arch Bronconeumol, 39 (2003), pp. 35-41 57
[31]
PMA Calverley.
Modern treatment of chronic obstructive pulmonary disease.
Eur Respir J, 18 (2001), pp. 60s-66s
[32]
PJ Barnes.
Future advances in COPD therapy.
Respiration, 68 (2001), pp. 441-448
[33]
PJ Barnes.
New treatments for chronic obstructive pulmonary disease.
Curr Opin Pharmacol, 1 (2001), pp. 217-222
[34]
PJ Barnes.
Therapy of chronic obstructive pulmonary disease.
Pharmacology & Therapeutics, 97 (2003), pp. 87-94
[35]
TM Ziedalski, V Sankaranarayanan, RK Chitkara.
Advances in the management of chronic obstructive pulmonary disease.
Exper Opin Pharmacother, 4 (2003), pp. 1063-1082
[36]
MDL Morgan, JR Britton.
Chronic obstructive pulmonary disease 8: non-pharmacological management of COPD.
Thorax, 58 (2003), pp. 453-457
[37]
W MacNee, PMA Calverley.
Chronic obstructive pulmonary disease 7: management of COPD.
Thorax, 58 (2003), pp. 261-265
[38]
LE Donnelly, DF Rogers.
Therapy for chronic obstructive pulmonary disease in the 21st century.
Drugs, 63 (2003), pp. 1973-1998
[39]
DD Sin, FA McAlister, SF Paul Man, NR Anthonisen.
Contemporary management of chronic obstructive pulmonary disease.
JAMA, 290 (2003), pp. 2301-2312
[40]
EJ Wagena, MPA Zeegers, CP van Schayck, EFM Wouters.
Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.
Drugs Safety, 26 (2003), pp. 381-403
[41]
DP Tashkin, R Kanner, W Bailey, S Buist, P Anderson, MA Nides, et al.
Smoking cessation in patients with chronic obstructive pulmonary disease: a double blind placebo-controlled, randomised trial.
Lancet, 357 (2001), pp. 1571-1575
[42]
F García Río, S Serrano, O Mediano, A Alonso, J Villamor.
Safety profile of bupropion for chronic obstructive pulmonary disease.
Lancet, 358 (2001), pp. 1009
[43]
DP Tashkin, BD Jamerson, MJ Patel.
Safety profile of bupropion hydrochloride for chronic obstructive pulmonary disease.
Lancet, 358 (2001), pp. 1009-1010
[44]
D O'Donnell.
Ventilatory limitations in chronic obstructive pulmonary disease.
Med Sci Sports Exerc, 33 (2001), pp. 647-655
[45]
CA Jiménez Ruiz, F Masa, M Miravitlles, R Gabriel, JL Viejo, C Villasante, et al.
Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD.
Chest, 119 (2001), pp. 1365-1370
[46]
CA Jiménez Ruiz, V Sobradillo Peña, M Miravitlles, R Gabriel, C Villasante, F Masa, et al.
Análisis de tabaquismo en España a la luz de los resultados del estudio IBERPOC.
Prev Tab, 2 (2000), pp. 189-193
[47]
JG van Manen, PJ Bindels, FW Dekker, CJ Ijzermans, JS van der Zee, E Shade.
Risk of depression in patients with chronic obstructive pulmonary disease and its determinants.
Thorax, 57 (2002), pp. 412-416
[48]
JG van Manen, PJ Bindels, CJ Ijzermans, JS van der Zee, BJ Bottema, E Schade.
Prevalence of comorbidity in patients with chronic airway obstruction and controls over the age of 40.
J Clin Epidemiol, 54 (2001), pp. 287-293
[49]
JD Killen, SP Fortmann, HC Kraemer, A Varady, B Newman.
Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation.
J Consult Clin Psychol, 60 (1992), pp. 797-801
[50]
N Breslau, EO Johnson.
Predicting smoking cessation and major depression in nicotine-dependent smokers.
Am J Public Health, 90 (2000), pp. 1122-1127
[51]
JD Killen, SP Fortmann, HC Kraemer, A Varady, L Davis, B Newman.
Interactive effects of depression symptoms, nicotine dependence, and weight change on late smoking relapse.
J Consult Clin Psychol, 64 (1996), pp. 1060-1067
[52]
N Walters, T Coleman.
Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not.
Br J Gen Pract, 52 (2002), pp. 132-134
[54]
J Clotet, X Gómez-Arbones, C Ciria, JM Albalad.
La espirometría es un buen método para la detección y el seguimiento de la EPOC en fumadores de alto riesgo en Atención Primaria.
Arch Bronconeumol, 40 (2004), pp. 155-159
[55]
JI Jaén Díaz, C de Castro Mesa, MJ Gontán García Salamanca, F López de Castro.
Prevalencia y factores de riesgo de EPOC en fumadores y ex fumadores.
Arch Bronconeumol, 39 (2003), pp. 554-558
[56]
C Bolman, C Sino, P Hekking, A van Keimpema, J van Meerbeeck.
Willingness of pulmonologist to guide COPD patients in smoking cessation.
Patient Educ Couns, 57 (2005), pp. 126-133
[57]
NR Anthonisen, JE Connett, JP Kiley, MD Altose, WC Bailey, AS Buist, et al.
Effects of smoking cessation intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.
JAMA, 272 (1994), pp. 1497-1505
[58]
RP Murray, WC Bailey, K Daniels, WM Bjornson, K Kurnow, JE Connett, et al.
Safety of poliacrilex gum used by 3094 participants in the Lung Health Study.
Chest, 109 (1996), pp. 438-445
[59]
E Monninkhof, P van der Valk, J van der Palen, H Mulder, M Pieterse, C van Herwaarden, et al.
The effects of a minimal contact smoking cessation programme in out patients with chronic obstructive pulmonary disease: pre-post-test study.
Patient Educ Counsel, 52 (2004), pp. 231-236
[60]
D Gorecka, M Bednarek, A Nowinski, E Puscisnska, A Goljan-Geremek, J Zielinski.
Diagnosis of airflow limitation combined with smoking cessation advice increases stop smoking rate.
Chest, 123 (2003), pp. 1916-1923
[61]
I Nerín, P Novella, A Crucelaegui, A Beamonte, N Sobradiel, P Gargallo.
Factores predictores de éxito a los 6 meses en fumadores tratados en unidad de tabaquismo.
Arch Bronconeumol, 40 (2004), pp. 558-562
[62]
SE Sherman, AB Lanto, M Nield, EM Yano.
Smoking cessation care received by veterans with chronic obstructive pulmonary disease.
J Rehabil Res Dev, 40 5 (2003), pp. 1-12
[63]
D Gorecka, M Bednarek, A Nowinski, E Puscinska, A Goljan-Geremek, J Zielinski.
Effect of treatment for nicotine dependence in patient with COPD [abstract].
Pneumonol Alergol Pol, 71 (2003), pp. 411-417
[64]
S Sato, K Nishimura, H Koyama, M Tsukino, T Oga, T Hajiro, et al.
Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD.
Chest, 124 (2003), pp. 1749-1754
[65]
MA Javors, JP Hatch, RJ Lamb.
Cut-off levels for breath carbon monoxide as a marker for cigarette smoking.
Addiction, 100 (2005), pp. 159-167
[66]
RM van der Meer, EJ Wagena, RWJG Ostelo, JE Jacobs, CP van Schayck.
Smoking cessation for chronic obstructive pulmonary disease (Cochrane Reviews).
The Cochrane Library, Issue 4, John Wiley & Sons, (2003),
[67]
LL Pederson, JM Wanklin, NM Lefcoe.
The effects of counselling on smoking cessation among patients hospitalised with chronic obstructive pulmonary disease: a randomised clinical trial.
Int J Addictions, 20 (1991), pp. 107-119
[68]
TJ Crowley, MJ MacDonald, MI Walter.
Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients.
Psychopharmacology, 119 (1995), pp. 193-204
[69]
CJ Brandt, H Ellegaard, M Joensen, FV Kallan, AD Sorknaes, L Tougaard.
Effect of diagnosis of smoker's lung. RYLUNG Group.
Lancet, 349 (1997), pp. 253
[70]
RE Kanner, JE Connet, DE Williams, S Buist, for the Lung Study Research Group.
Effects of randomised assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study.
Am J Med, 106 (1999), pp. 410-416
[71]
PD Scanlon, JE Connett, LA Waller, MD Altose, A Bailey, S Buist, et al.
Smoking cessation and lung function in mild to moderate chronic obstructive pulmonary disease (The Lung Health Study).
Am J Respir Crit Care Med, 161 (2000), pp. 381-390
[72]
RA Wise, RE Kanner, P Lindgren, JE Connett, MD Altose, PL Enright, et al.
The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD (The Lung Health Study).
Chest, 124 (2003), pp. 449-458
[73]
M Llombart, J Signes-Costa, E Chiner, E Pastor, C Romero, AL Andreu, et al.
Eficacia de diferentes tratamientos para el tabaquismo en pacientes con EPOC.
Arch Bronconeumol, 40 (2004), pp. 95
[74]
JD Anczak, RA Nogler.
Tobacco cessation in primary care: maximizing interventions strategies.
Clin Med Res, 1 (2003), pp. 201-216
[75]
Conferencia de Consenso sobre EPOC, España, 25-26 Noviembre 2002. Procedimientos.
Arch Bronconeumol, 39 (2003), pp. 1-47
[76]
FL Urbano, RM Pascuel.
Contemporary issues in the care of patients with chronic obstructive pulmonary disease.
J Manag Care Pharm, 115 (2005), pp. S2-S13
[77]
CM de San Román y Terán, R Guijarro Merino, JM Pérez Díaz.
Coste de la hospitalización por EPOC en Andalucía 1998 a 2002.
Arch Bronconeumol, 41 (2005), pp. 236
[78]
M Decramer, R Gosselink, P Bartsch, CG Lofdahl, W Vincken, R Dekhuijzen, et al.
Effects of treatments on the progression of COPD; report of a workshop held in Leuven.
Thorax, 60 (2005), pp. 343-349
[79]
BW Willemse, NH Ten Hacken, B Rutgers, IG Lesman-Leegte, W Timens, DR Postma.
Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD.
Eur Respir J, 24 (2004), pp. 391-396
[80]
BW Willemse, DS Postma, W Timens, NH Ten Hacken.
The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation.
Eur Respir J, 23 (2004), pp. 464-476
[81]
NR Anthonisen, MA Skeans, RA Wise, J Manfreda, RE Kanner, JE Connet.
The effects of a smoking cessation intervention on 14.5 years mortality.
Ann Intern Med, 142 (2005), pp. 233-239
[82]
CP Hersh, DL Demeo, E Al Ansari, VJ Carey, JJ Reilly, LC Ginns, et al.
Predictors of survival in severe, early onset COPD.
Chest, 126 (2004), pp. 1443-1451
[83]
EJ Wagena, RM van der Meer, RJ Ostelo, JE Jacobs, CD van Schayck.
The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review.
Respir Med, 98 (2004), pp. 805-815
[84]
H Jonsdottir, R Jonsdottir, T Geirsdottir, KS Sveinsdottir, T Sigurdardottir.
Multicomponet individualized smoking cessation interventions for patients with lung disease.
J Adv Nurs, 48 (2004), pp. 594-604
[85]
ZA Solak, T Goksel, CG Telli, E Erdinc.
Success of smoking cessation program among smoking relatives of patients with serious smoking-related pulmonary disorders.
Eur Addict Res, 11 (2005), pp. 57-61
[86]
K Fagerström.
New perspective in the treatment of tobacco dependence.
Monaldi Arch Chest Dis, 60 (2003), pp. 19-83
[87]
K Fagerström.
Smoking reduction in the management of COPD.
Monaldi Arch Chest Dis, 57 (2002), pp. 281-284
[88]
CA Jiménez Ruiz, S Solano, S Alonso Viteri, M Barrueco Ferrero, M Torrecilla, M Hernández Mezquita.
Harm reduction, a treatment approach for resistant smokers with tobacco-related symptoms.
Respiration, 69 (2002), pp. 452-455
[89]
CA Jiménez Ruiz, M Kunze, KO Fagerström.
Nicotine replacement: a new approach to reducing tobacco related harm.
Eur Respir J, 11 (1998), pp. 473-479
[90]
MS Simmons, JE Connett, MA Nides, PG Lindgren, EC Kleerup, RP Murray, et al.
Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study.
Eur Respir J, 25 (2005), pp. 1011-1017
[91]
F Rico Méndez, S Barquera, J Mügica Hernández, J Espinosa Pérez, S Ortega, L Ochoa.
Supervivencia de una cohorte con EPOC: análisis comparativo entre el primer y tercer niveles de atención.
Arch Bronconeumol, 41 (2005), pp. 260-266
[92]
J de Miguel Díez, JL Izquierdo Alonso, J Molina Paris, JM Bellón Cano, JM Rodríguez González-Moro, P de Lucas Ramos.
Factores determinantes de la prescripción farmacológica en los pacientes con EPOC estable: resultados de un estudio multicéntrico español (IDENTEPOC).
Arch Bronconeumol, 41 (2005), pp. 63-70
[93]
C Esteban, J Moraza, M Aburto, JM Quintana, A Capelastegui.
Descripción de una muestra de pacientes con enfermedad pulmonar obstructiva crónica atendidos en las consultas del área de neumología dependientes de un hospital.
Arch Bronconeumol, 39 (2003), pp. 485-490
[94]
C Sanjuas Benito.
Medición de la calidad de vida: ¿cuestionarios genéricos o específicos?.
Arch Bronconeumol, 41 (2005), pp. 107-109
[95]
J de Miguel Díez, JL Izquierdo Alonso, JM Rodríguez González-Moro, P de Lucas Ramos, JM Bellón Cano, J Molina Paris.
Calidad de vida en la enfermedad pulmonar obstructiva crónica. Influencia del nivel de asistencia de los pacientes.
Arch Bronconeumol, 40 (2004), pp. 431-437
[96]
M Barrueco Ferrero, CA Jiménez Ruiz, L Palomo Cobos, M Torrecilla García, P Romero Palacios, JA Riesco Miranda.
Abstinencia puntual y continuada en el tratamiento farmacológico del tabaquismo en la práctica clínica.
Med Clin (Barc), 123 (2004), pp. 652-656
[97]
M Decramer, P Bartsch, R Pauwels, JC Yernault, the COPD advisory board.
Management of COPD according to guidelines. A national survey among Belgian physicians.
Monaldi Arch Chest Dis, 59 (2003), pp. 1,62-1,80
[98]
OT Ruschmann, JP Janssens, B Vermeulen, FP Sarasin.
Knowledge of guidelines for the management of COPD: a survey of primary care physicians.
Respir Med, 98 (2004), pp. 932-937
[99]
JI Granda Orive, T Peña Miguel, C Reinares Ten, JA Escobar Sacristán, JM Martínez Albiach, R Sáez Valls, et al.
Reciben consejo médico los asmáticos jóvenes.
Prev Tab, 2 (2000), pp. 17-21
[100]
A Más, I Nerín, M Barrueco, J Cordero, D Guillén, CA Jiménez-Ruiz, et al.
Consumo de tabaco en estudiantes de sexto de medicina en España.
Arch Bronconeumol, 40 (2004), pp. 403-408
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
